Latest Period
Q2 2026
Security Snapshot
NEKTAR THERAPEUTICS - Common Stock, $0.0001 par value (NKTR) Institutional Ownership
CUSIP: 640268306
13F Institutional Holders and Ownership History from Q2 2025 to Q2 2026
Institutions Reporting
239
Shares (Excl. Options)
35,867,344
Price
$69.81
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value
- Symbol
- NKTR on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 35,867,344
- Total 13F value
- $2,503,856,816
- Portfolio coverage rank
- 0.01%
- Share change
- +9,266,919
- Value change
- +$645,003,114
- Number of holders
- 239
- Shares outstanding
- 33,980,593
- SEC-reported price per share
- $75.92
- Insider filing price
- $75.92
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- NKTR - NEKTAR THERAPEUTICS - Common Stock, $0.0001 par value is tracked under CUSIP 640268306.
- 239 institutions reported positions in Q2 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 207 to 239 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $1,919,374,892 to $2,503,856,816.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 239 institutions filings for Q2 2026.
Security key
640268306
Latest holder period
Q2 2026
13F holders
239
13D/G owners
9
CIK / CUSIP context first
Open Q2 2026 holders
NKTR full holder history
NEKTAR THERAPEUTICS SEC filings
NEKTAR THERAPEUTICS company facts
NEKTAR THERAPEUTICS insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 640268306:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
9
Security
NKTR
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | +35% | $331,302,473 | +$97,502,292 | 4,303,188 | +42% | FMR LLC | 31 Mar 2026 |
| Two Seas Capital LP | 9.1% | $222,331,625 | 3,092,234 | Two Seas Capital LP | 30 Jun 2026 | |||
| BlackRock, Inc. | 7.8% | +310% | $184,563,399 | +$170,390,782 | 2,643,796 | +1202% | BlackRock, Inc. | 30 Jun 2026 |
| BIOTECHNOLOGY VALUE FUND L P | 7.1% | -4.3% | $171,918,292 | +$80,131,112 | 2,391,075 | +87% | BVF PARTNERS L P/IL | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.2% | $125,656,251 | 1,747,653 | Vanguard Capital Management | 30 Jun 2026 | |||
| VANGUARD GROUP INC | 5% | +1.2% | $43,425,528 | +$3,316,543 | 1,027,089 | +8.3% | The Vanguard Group | 31 Dec 2025 |
| SUSQUEHANNA SECURITIES, LLC | 4% | -38% | $34,245,405 | -$18,006,925 | 809,967 | -34% | G1 Execution Services, LLC | 31 Dec 2025 |
| INTEGRATED CORE STRATEGIES (US) LLC | 3% | -48% | $32,489,559 | -$20,590,346 | 570,994 | -39% | Millennium Management LLC | 30 Sep 2025 |
| Nantahala Capital Management, LLC | 2.2% | -59% | $23,813,902 | -$16,571,499 | 418,522 | -41% | Nantahala Capital Management, LLC | 30 Sep 2025 |
As of 30 Jun 2026, 239 institutional investors reported holding 35,867,344 shares of NEKTAR THERAPEUTICS - Common Stock, $0.0001 par value (NKTR). This represents 106% of the company’s total 33,980,593 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
79%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 5,067,920 | +18% | 0.02% | $353,791,520 |
| Two Seas Capital LP | 9.1% | 3,092,234 | +58% | 8.2% | $215,868,856 |
| BlackRock, Inc. | 8.7% | 2,941,851 | +325% | 0% | $205,370,620 |
| BVF INC/IL | 7% | 2,391,075 | -6.6% | 4.3% | $166,920,946 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.4% | 1,496,849 | +25% | 0% | $104,495,029 |
| TWO SIGMA INVESTMENTS, LP | 3.5% | 1,202,004 | +29% | 0.06% | $83,911,899 |
| Vestal Point Capital, LP | 2.9% | 1,000,000 | +251% | 1.6% | $69,810,000 |
| MORGAN STANLEY | 2.8% | 936,560 | +42% | 0% | $65,381,263 |
| STATE STREET CORP | 2.7% | 909,679 | +272% | 0% | $63,504,691 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.6% | 881,306 | +154% | 0% | $61,536,312 |
| Prosight Management, LP | 2.4% | 810,000 | +10% | 9.7% | $56,546,100 |
| ARMISTICE CAPITAL, LLC | 2.1% | 724,000 | +25% | 1.4% | $50,542,440 |
| GILDER GAGNON HOWE & CO LLC | 1.8% | 600,873 | +121% | 0.43% | $41,946,944 |
| MILLENNIUM MANAGEMENT LLC | 1.4% | 478,120 | +18% | 0.02% | $33,377,557 |
| BRAIDWELL LP | 1.4% | 473,617 | +113% | 1.2% | $33,063,203 |
| Sofinnova Investments, Inc. | 1.4% | 471,763 | -7.4% | 1.8% | $32,933,775 |
| Woodline Partners LP | 1.4% | 470,875 | +13% | 0.1% | $32,871,784 |
| ORBIMED ADVISORS LLC | 1.4% | 465,346 | +69% | 0.62% | $32,485,804 |
| UBS Group AG | 1.3% | 428,400 | +34% | 0% | $29,906,604 |
| EMERALD ADVISERS, LLC | 1.1% | 390,158 | -1.1% | 0.64% | $27,236,930 |
| LORD, ABBETT & CO. LLC | 1.1% | 381,624 | -5.8% | 0.08% | $26,641,000 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1% | 348,540 | +381% | 0% | $24,331,577 |
| DAFNA Capital Management LLC | 0.94% | 318,380 | +93% | 4.2% | $22,226,108 |
| NORTHERN TRUST CORP | 0.91% | 308,531 | +293% | 0% | $21,538,548 |
| Deep Track Capital, LP | 0.88% | 300,000 | 0.31% | $20,943,000 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
5
Latest
Q2 2026
Rows shown
1-5 of 5
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 35,867,344 | $2,503,856,816 | +$645,003,114 | $69.81 | 239 |
| 2026 Q1 | 26,699,855 | $1,919,374,892 | +$690,423,805 | $71.95 | 207 |
| 2025 Q4 | 17,311,424 | $731,897,039 | +$83,234,784 | $42.28 | 171 |
| 2025 Q3 | 14,405,809 | $819,769,158 | +$416,306,829 | $56.90 | 143 |
| 2025 Q2 | 7,657,053 | $197,846,106 | +$197,839,388 | $25.84 | 100 |